Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Liquid Biopsy Company Delfi Diagnostics Raised $100M For New Class Of Early Cancer Detection Test

Executive Summary

Delfi Diagnostics will use the new funds to expand its team of cancer researchers and machine-learning experts to validate its novel approach for early cancer detection through multiple prospective clinical trials. 

You may also be interested in...



Financing Quarterly Statistics: Q1 Highlights Include 3 Medtech And 7 IVD IPOs

To open the year, medical device company fundraising totaled $2.8bn; while in vitro diagnostic firms and research tools players raised $7bn.

Early Cancer Detection: Will New Screening Technology Disrupt Cancer Care?

The emergence of multi-cancer blood tests for early detection is captivating investors and driving multi-billion-dollar acquisitions. Companies such as GRAIL, Thrive Earlier Detection and Guardant are predicting revolutionary change in the way cancer is diagnosed and treated. The biggest hurdle, however, may be coaxing health care systems and health insurers to join the revolution.

Playing Big: Akili To Be Bought By Chamath Palihapitiya’s SPAC In $1Bn Deal

Akili Interactive, which developed a video game to treat ADHD, will go public with one of Palihapitiya’s blank-check companies. The proceeds will be used to launch the FDA-cleared EndeavorRx digital therapeutics.

Topics

UsernamePublicRestriction

Register

MT143345

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel